Despite advances in surgical techniques and molecular targeted therapy, gastric cancer (GC) remains one of the most lethal malignancies worldwide, causing 750,000 deaths annually [1–3]. Tumor recurrence in the peritoneum occurs in 40 %–60 % of advanced GC patients who have undergone radical surgery [4–6], and patients who develop peritoneal recurrence (PR) have a median overall survival (OS) of only 3–9 months [7,8]. Therefore, timely and appropriate preventive interventions to reduce the risk o…